Shigeno Kohichiro

K Pharma is a clinical-stage biopharmaceutical company based in Japan that focuses on the development of regenerative medicine and innovative drug discovery using induced pluripotent stem cell (iPSC) technology. The company was established to commercialize the research of Professor Hideyuki Okano from Keio University School of Medicine, particularly in the field of central nervous system disorders. K Pharma's lead program, KP401 (ropinirole hydrochloride), is a small molecule being repurposed for Amyotrophic Lateral Sclerosis (ALS) after being identified through an iPSC-based phenotypic screening platform. Additionally, the company is advancing KP801, an iPSC-derived neural stem/progenitor cell therapy for the treatment of subacute spinal cord injuries. By integrating iPSC-based drug screening with cell therapy, K Pharma aims to provide new therapeutic options for patients with intractable diseases. The company is listed on the Tokyo Stock Exchange and maintains strong academic ties to Keio University.